Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer? - Wikidata - awgldk - TriplyDB

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

http://www.wikidata.org/entity/Q28085104

about

Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.

P2860

Q42359608-A52FB568-BE95-4D46-9A83-5061DBE6A34F Q45711840-84F251CD-0313-4C04-BAB2-8DFCE57C9B9C

P2860

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

http://www.wikidata.org/entity/Q28085104

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

@ast

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

@en

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

@nl

type

label

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

@ast

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

@en

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

@nl

prefLabel

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

@ast

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

@en

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

@nl

P1433

Q28085104-12C7E488-1E05-468B-9824-587F9BDE1CA2

P1476

Q28085104-0212F99A-35E9-4EE4-B1B6-00D829F8C416

P2093

Q28085104-1E716A5D-2F86-48E7-B77C-6BEA537BA364

Q28085104-F81DEC8E-4D78-45A3-A4C8-2CE62CEFD35A

Q28085104-F97B2876-C02B-452E-902C-8D9FC23793D1

P275

Q28085104-536954B5-4AC7-4DBD-BA2E-A8F9B885F8F1

P2860

Q28085104-046EF58A-A763-4D9C-8166-A27CAB721282

Q28085104-0C531766-3116-4258-BA89-E1053FAD2D70

Q28085104-127213F1-357D-4976-8F78-4D45C8A6D3CB

Q28085104-147ABBD2-3949-4B0D-B22F-09AF1ED1D7E9

Q28085104-1CCFB795-A571-42B5-80CF-5D12BC1ACB06

Q28085104-1F1F1C2F-DDBF-4BCA-BCB0-628826548BA5

Q28085104-2A7F5045-DAB8-48E2-A0F7-E5F0E279143C

Q28085104-2D7F558D-4794-4202-88AA-4A99E5E51D0B

Q28085104-2EDA3495-DEAA-46FF-A366-C2B593AC0E2C

Q28085104-310E35DE-DB59-483C-8DEA-D6BD17092F5D

P304

Q28085104-6817DB47-99FA-4FB9-9053-794F9255DBD9

P31

Q28085104-5E148BFC-48BD-4117-95C2-35404299B0F6

Q28085104-E7E093FF-7EE8-4E72-A00C-97C68B06A526

Q28085104-bba4fb7f-feee-493e-88f2-be910337d2fb

P356

Q28085104-E6C08304-9DD8-47AA-9F39-CD2D72407EA8

P407

Q28085104-1191C7CF-84E4-4A6A-A18B-61A4D960E590

P433

Q28085104-F1FEBFA8-8B4E-4D86-8ABE-2EA78752B6B4

P478

Q28085104-C879C3AD-E38B-4607-B67D-A0550F8C775D

P5008

Q28085104-FCE94B3B-F2FC-4593-BBBE-7F3AC5E373D9

P577

Q28085104-3EC69C59-0938-4AC6-9A33-665D3706EB4A

P5875

Q28085104-1A75A016-9106-4E47-BB16-6B272D00CB6E

P698

Q28085104-76708CD1-4326-4BE2-9016-EBB62B65F033

P921

Q28085104-27262CB3-F29F-461A-860A-B5F2503D1EF1

Q28085104-2FD8C983-B0AF-4830-87B8-65A221DE0990

Q28085104-7FC727B9-824C-4B00-AB29-17077B31F62B

Q28085104-ABF9B2FA-A3BD-4807-9A73-BD2B445B9146

Q28085104-D98A655A-93A7-4DA1-BA9D-A8391BB16B05

Q28085104-E2CE6666-7621-477E-8D5D-727A1588B8BD

Q28085104-F3576D3B-CE7F-4957-96B0-F0994C089EE4

P932

Q28085104-68860E20-B88F-4355-8CEC-74ED0EA38EFF

P356

ONCOTARGET.4524

P1433

P1476

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

@en

P2093

Shuai Wang

http://www.w3.org/2001/XMLSchema#string

Zhe Yang

http://www.w3.org/2001/XMLSchema#string

Zhou Wang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Modes of resistance to anti-angiogenic therapy

Bias in meta-analysis detected by a simple, graphical test

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Cancer statistics, 2008

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Practical methods for incorporating summary time-to-event data into meta-analysis

How should meta-regression analyses be undertaken and interpreted?

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

P304

18206-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.4524

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279987627

http://www.w3.org/2001/XMLSchema#string

P698

26156021

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

mechanism of action

non-small-cell lung carcinoma

membrane proteins

P932

4627246

http://www.w3.org/2001/XMLSchema#string